This is a routine clinical update with no material new data, the stock is unlikely to move on this announcement alone. Monitor Phase 2b data readouts in mid-2027 (AD) and late 2027 (asthma) as the next major catalysts. No trading action warranted.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $86.21entry
- T+1 · 5mo ago −0.71%α −2.48% · $85.59
- T+5 · 5mo ago +4.90%α +4.23% · $90.43
- T+20 · 4mo ago +38.45%α +36.67% · $119.35
- T+60 · 2mo ago +35.11%α +31.84% · $116.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kymera presented Phase 1 data for KT-621 (oral STAT6 degrader) in healthy Japanese adults at the JDA Annual Meeting, showing safety and PK/PD results consistent with prior studies. The data supports global Phase 2b trials (BROADEN2 in atopic dermatitis, BREADTH in asthma) that are ongoing with readouts expected by mid-2027 and late 2027, respectively. This is an incremental data update with no new efficacy or regulatory catalyst, a routine clinical-stage update for a $6.8B biotech.
Key Facts
- Phase 1 study in 24 healthy Japanese adults showed median STAT6 degradation ≥98% at both dose levels at Day 7, consistent with prior non-Japanese studies.
- KT-621 was well tolerated with a favorable safety profile across both doses.
- Parallel Phase 2b trials BROADEN2 (atopic dermatitis) and BREADTH (asthma) are ongoing; data expected by mid-2027 and late 2027, respectively.
- No new efficacy data, regulatory milestone, or financial guidance was disclosed in this press release.
Financial Impact
No financial figures disclosed; this is a clinical data update with no immediate revenue or cost impact.
Risk Factors
- Phase 2b data may fail to replicate Phase 1 efficacy or safety signals.
- Competition from other oral STAT6/Type 2 inflammation programs (e.g., from Roche, Sanofi) could limit commercial potential.
- Cash burn from ongoing trials without near-term revenue may pressure the stock if financing is needed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310977 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers